Cyto Wave Technologies Announces Exclusive Letter of Intent With UC San Francisco

SAN FRANCISCO, July 8, 2014 /PRNewswire-iReach/ -- Cyto Wave Technologies Inc. (the "Company") (OTCQB: CWAV) announced today that it entered into an exclusive letter of intent ("LOI") with the University of California, San Francisco ("UCSF") in regards to the exclusive global licensing of a medical stereotactic device (the "UCSF Device") which the Company believes has the potential to revolutionize the delivery of stem cells into the human brain and enhance the efficacy of a wide range of stem cell therapeutics. As part of the Company's strategy to develop and commercialize innovative medical device applications, beyond stem cells, the platform technology of the UCSF Device can also enable the delivery of cellular therapeutics, gene therapies, and traditional drug infusions into the human brain.

The Stem Cell industry is one of the fastest growing and most compelling areas in medicine with numerous companies and research institutions spending hundreds of millions of dollars per year on the development of new therapies and devices. The Company believes that the UCSF Device could become the preferred tool for the deployment of stem cells into the human brain for any company or clinician conducting clinical trials and providing experimental treatment in this field. Therefore, the use of the UCSF Device could become analogous to the use of 'picks and shovels' during the historical gold rush and allow the Company to participate in the growth of the Stem Cell industry as a provider of tools and resources.

The Opportunity in the Stem Cell Market

There are numerous companies worldwide that are currently doing research with Regenerative Medicine and Stem Cell technologies. According to the VisionGain Stem Cell Industry Report 2012-2013, the estimated market size for regenerative medicine is $10.7 billion in 2017 ramping up to approx. $22 billion by 2020.

About The UCSF Device

Over 9 million patients in the United States suffer from a wide range of neurological disorders including Alzheimer's disease, Parkinson's disease, epilepsy, and multiple sclerosis. Promising stem cell therapies for these disorders are being developed, but most require direct delivery of such cell-based therapeutics to specific brain regions.

Currently available neurosurgical devices can deliver a straight, rigid needle to single brain locations. However, this basic strategy limits the size and "shape" of the brain treatment area. In order to deliver to larger and more complex brain targets, the surgeon needs to penetrate the brain multiple times with such straight needles, which may reduce the efficacy of stem cell therapeutics and increase the risk of bleeding and stroke.

The UCSF Device enables the radial deployment of a flexible delivery catheter to large and anatomically complex brain targets through a single initial brain penetration. Thus, the UCSF Device allows clinicians to "tailor" therapeutic stem cell delivery to individual patient anatomy and specific disease targets, which may enhance the efficacy of a wide range of stem cell therapies. This modern and "easy to use" platform technology allows "real-time" monitoring of therapeutic delivery under interventional MRI guidance.

To date, the UCSF Device has been developed at UCSF with $1.8 million in funding from the California Institute for Regenerative Medicine (CIRM).

CIRM was created by California's Proposition 71 in 2004, which authorized it to issue $3 billion in grants over ten years for embryonic stem cell and other biomedical research. It is believed to be the world's largest single backer of research in stem cells.

Read more:
Cyto Wave Technologies Announces Exclusive Letter of Intent With UC San Francisco